Proposition 38, an $8.4 billion general obligation bond for immunology and immunotherapy research targeting cancer, heart disease, and Alzheimer’s, appears on California’s November 3, 2026 ballot after qualifying in June. Trader sentiment at 56.5% for passage reflects endorsements from the California Democratic Party, disease advocacy organizations, and research institutions alongside the measure’s structure, which directs half the proceeds to a UC-affiliated institute and requires drug discounts plus revenue sharing to offset costs. Recent voter guides and analyses highlight the $500–600 million annual General Fund repayment over roughly two decades, plus debate over competitive grant allocation versus dedicated funding for one entity. Federal research funding reductions have bolstered arguments for state-level support, yet concerns over debt service and budget priorities keep the outcome closely contested ahead of the election.